Discontinued Operations (Details) - USD ($) $ in Millions		12 Months Ended
	Jul. 06, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Discontinued Operations
Gain (loss) on sale of business		$ 47.5	$ (20.9)	$ 71.7
Foreign currency translation gain	$ 159.3
Purchase of inventory		2.4	$ 170.6	$ 67.0
Prepaid expenses and other current assets
Discontinued Operations
Receivable from transition services agreement		2.3
RX Pharmaceuticals | Discontinued Operations, Disposed of by Sale
Discontinued Operations
Total consideration in definitive agreement to sell	1,550.0
Potential R&D milestone payments and contingent purchase obligations assumed by purchaser	53.3
Gain (loss) on sale of business	$ 47.5
Transition service period	24 months
Supply agreement term	4 years
Supply agreement, extension period	7 years
Proceeds from transition services agreement		3.6
Proceeds from supply and distribution agreements		28.7
Payments for supply arrangements		12.0
Aggregate cap on buyer's obligation for certain pre-closing liabilities (percent)	50.00%
Aggregate cap on buyer's obligation for certain pre-closing liabilities	$ 50.0
Separation costs		40.8
RX Pharmaceuticals | Discontinued Operations, Disposed of by Sale | Other Operating Expense (Income)
Discontinued Operations
Income from transition services agreement		7.2
RX Pharmaceuticals | Discontinued Operations, Disposed of by Sale | Net Sales
Discontinued Operations
Product sales and royalty income from transition services agreement		60.6
RX Business | Discontinued Operations, Disposed of by Sale | RX Pharmaceuticals
Discontinued Operations
Purchase of inventory		$ 18.4